Medical Information
France
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you

This content is intended for French Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

European Medicines Agency (EMA) has issued a Conditional Marketing Authorisation (CMA) to permit use of the product COMIRNATY COVID-19 mRNA Vaccine for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. During the initial pandemic stage, COMIRNATY COVID-19 mRNA Vaccine may also be distributed with the packaging with the name Pfizer-BioNTech COVID-19 Vaccine.

COMIRNATY (COVID-19 mRNA vaccine)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

COMIRNATY Quick Search

Due to the recent approval of the vaccine by the EMA and European Commission, the Summary of Product Characteristics for COMIRNATY available here, will be available soon on the French Public database of medications.



Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event